{"success":true,"data":{"pressRelease":{"id":"30218","rtpr_id":"nGNXnV5H9","ticker":"GOSS","exchange":"NASDAQ","all_tickers":["GOSS"],"title":"GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Analysts Allegedly Misled by Trial Claims: Levi & Korsinsky","author":"Globe Newswire","published_at":"2026-05-11T20:00:00.546Z","article_body":"NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- On February 24, 2026, Wedbush\ndowngraded Gossamer Bio, Inc. (NASDAQ: GOSS) to Neutral and slashed its price\ntarget from $6 to $1. Oppenheimer followed on March 5, 2026, cutting its\ntarget from $12 to $3. These dramatic reversals came after GOSS shares had\nalready lost over 80% of their value in a single trading session. Find out if\nyou qualify to recover your per-share losses\n(https://www.globenewswire.com/Tracker?data=aJUf9GPyWR2Xkrls4sWUTVOGuSvV2MlxUntWwtX3KJYC2LU73bdNJftN7oM1ismBTU-1ZeCpNBg5j-yfkVOUBECayISCV7voy8hGRetPOJR2zH1DzUx8tftr1RG4c81Y03KfEok26Qm0HzJ9dlcO20U_xqPZvm1P-_XiTH1TTkir1HcGmztCO0o0SKAZhZgEhE9s71fHXwayT4idp2zLyDu_2IbietVptrxXAi0Zd4M=)\nor contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.\n\nGossamer stock fell $1.71 per share, from $2.13 to $0.42, on February 23,\n2026, after the Company disclosed that its Phase 3 PROSERA study failed to\nmeet the primary endpoint. The lead plaintiff deadline is June 1, 2026.\n\nInitial Analyst Optimism\n\nThroughout the Class Period from June 16, 2025 through February 20, 2026,\nsell-side coverage maintained a constructive stance on Gossamer. Analysts\nrelied on management's repeated assurances about patient selection and trial\nexecution. When the Company announced enrollment completion in June 2025,\ncoverage reflected confidence that PROSERA's design, built on Phase 2 TORREY\ninsights, positioned seralutinib for a successful readout. Multiple firms\nmaintained Buy-equivalent ratings with price targets well above the trading\nprice.\n\nThe Downgrades Begin\n\nThe February 23, 2026 topline disclosure shattered analyst confidence. Wedbush\nstated bluntly: \"PROSERA falls short of expectations,\" noting the +13.3 meter\nplacebo-adjusted gain failed the prespecified 0.025 alpha threshold with a\np-value of 0.0320. The firm highlighted management's acknowledgment of\n\"unusual placebo performance, particularly among Latin America and Asia/Middle\nEast regions\" and referenced historic Phase 3 placebo responses ranging from\nnegative 9 meters to positive 11 meters, far below what PROSERA's placebo arm\nproduced.\n\nExecution Concerns on Wall Street\n\nOppenheimer's March 5, 2026 report was more pointed. The firm characterized\nthe Latin American data irregularity as \"a trial execution issue, not a drug\neffect issue,\" noting that key opinion leaders believed the anomaly pointed to\n\"human measurement error during 6MWD lap counting.\" This framing raised\nserious questions about clinical site monitoring and oversight, issues the\nlawsuit contends management knew or recklessly disregarded throughout the\nClass Period.\n\nWhy Analyst Shifts Matter for Investors\n* Wedbush cut its price target by 83%, from $6 to $1, and downgraded to\nNeutral\n* Oppenheimer reduced its target by 75%, from $12 to $3\n* Both firms identified the Latin American placebo response as the central\nproblem\n* Oppenheimer attributed the failure to trial execution rather than drug\nefficacy\n* Analyst models had been built on management's public assurances about\npatient selection quality\n* The severity of the downgrades reflects how far analyst expectations\ndiverged from the actual outcome\nThe lawsuit asserts that these analysts, like all public investors, were\nrelying on statements that omitted material information about the risk profile\nof Latin American enrollment sites.\n\n\"When analyst expectations are built on incomplete or misleading company\ndisclosures, the resulting corrections can cause significant investor harm.\nThe magnitude of these downgrades reflects the gap between what was\ncommunicated and what was known internally.\" -- Joseph E. Levi, Esq.\n\nJoin the GOSS recovery action\n(https://www.globenewswire.com/Tracker?data=0yYinrkuBwEvC96fjTjEM0MD-K2h226DDxwoRk6u90OENmKGtAknIIWrS-FOGPkceXwxSkgyLQ9dU9IF0j6k4mxmJBZ1ujfJyLOlUbNpEY0zzE9h5KJI7RJLAwtTwSOzW-jEZUIVvsIudMplCElgOAGraVXoPXA1q3YcdAMCcF7anch-roEEXgaRTvChb0sX)\nor call (212) 363-7500.\n\nABOUT LEVI & KORSINSKY, LLP -- Over the past 20 years, Levi & Korsinsky has\nsecured hundreds of millions of dollars for aggrieved shareholders. The firm\nhas extensive expertise in complex securities litigation and a team of over 70\nemployees. For seven consecutive years, Levi & Korsinsky has ranked in ISS\nSecurities Class Action Services' Top 50 Report. The last day to move for lead\nplaintiff is June 1, 2026.\n\nFrequently Asked Questions About the GOSS Lawsuit\n\nQ: How much did GOSS stock drop? A: Shares fell approximately 80%, a decline\nof $1.71 per share, after the Company disclosed that the Phase 3 PROSERA study\nfailed to meet the primary endpoint on February 23, 2026. Investors who\npurchased shares during the class period at artificially inflated prices may\nbe entitled to compensation.\n\nQ: What specific misstatements does the GOSS lawsuit allege? A: The complaint\nalleges Gossamer Bio made materially false or misleading statements regarding\nthe Phase 3 PROSERA trial design, patient selection quality, and trial\nexecution, while concealing that enrollment characteristics at Latin American\nsites created a high risk of an outsized placebo response. When the true state\nwas revealed, the stock price declined sharply.\n\nQ: What do GOSS investors need to do right now? A: Gather brokerage records\nincluding purchase dates, share quantities, and prices paid. Contact Levi &\nKorsinsky for a free, no-obligation evaluation at jlevi@levikorsinsky.com or\n(212) 363-7500. No immediate action is required to remain eligible as a class\nmember.\n\nQ: What if I already sold my GOSS shares -- can I still recover losses? A:\nYes. Eligibility is based on when you purchased, not whether you still hold\nthem. Investors who bought during the class period and sold at a loss may\nstill participate.\n\nQ: What does it cost me to participate? A: Nothing. Securities class actions\nare handled on a pure contingency basis. No upfront fees, no retainer, no\nout-of-pocket costs.\n\nQ: What if I missed the lead plaintiff deadline? A: The deadline applies only\nto investors seeking lead plaintiff appointment. Class members who miss it can\nstill participate in any settlement or recovery.\n\nCONTACT:\nLevi & Korsinsky, LLP\nJoseph E. Levi, Esq.\nEd Korsinsky, Esq.\n33 Whitehall Street, 27th Floor\nNew York, NY 10004\njlevi@levikorsinsky.com\nTel: (212) 363-7500\nFax: (212) 363-7171\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/d91bd4e6-7d18-43f7-a479-4f992242a82a)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXnV5H9","title":"GOSS Investor Alert: Gossamer Bio Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Analysts Allegedly Misled by Trial Claims: Levi & Korsinsky","author":"Globe Newswire","ticker":"GOSS","created":"2026-05-11T20:00:00.546Z","tickers":["GOSS"],"exchange":"NASDAQ","article_body":"NEW YORK, May 11, 2026 (GLOBE NEWSWIRE) -- On February 24, 2026, Wedbush\ndowngraded Gossamer Bio, Inc. (NASDAQ: GOSS) to Neutral and slashed its price\ntarget from $6 to $1. Oppenheimer followed on March 5, 2026, cutting its\ntarget from $12 to $3. These dramatic reversals came after GOSS shares had\nalready lost over 80% of their value in a single trading session. Find out if\nyou qualify to recover your per-share losses\n(https://www.globenewswire.com/Tracker?data=aJUf9GPyWR2Xkrls4sWUTVOGuSvV2MlxUntWwtX3KJYC2LU73bdNJftN7oM1ismBTU-1ZeCpNBg5j-yfkVOUBECayISCV7voy8hGRetPOJR2zH1DzUx8tftr1RG4c81Y03KfEok26Qm0HzJ9dlcO20U_xqPZvm1P-_XiTH1TTkir1HcGmztCO0o0SKAZhZgEhE9s71fHXwayT4idp2zLyDu_2IbietVptrxXAi0Zd4M=)\nor contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or (212) 363-7500.\n\nGossamer stock fell $1.71 per share, from $2.13 to $0.42, on February 23,\n2026, after the Company disclosed that its Phase 3 PROSERA study failed to\nmeet the primary endpoint. The lead plaintiff deadline is June 1, 2026.\n\nInitial Analyst Optimism\n\nThroughout the Class Period from June 16, 2025 through February 20, 2026,\nsell-side coverage maintained a constructive stance on Gossamer. Analysts\nrelied on management's repeated assurances about patient selection and trial\nexecution. When the Company announced enrollment completion in June 2025,\ncoverage reflected confidence that PROSERA's design, built on Phase 2 TORREY\ninsights, positioned seralutinib for a successful readout. Multiple firms\nmaintained Buy-equivalent ratings with price targets well above the trading\nprice.\n\nThe Downgrades Begin\n\nThe February 23, 2026 topline disclosure shattered analyst confidence. Wedbush\nstated bluntly: \"PROSERA falls short of expectations,\" noting the +13.3 meter\nplacebo-adjusted gain failed the prespecified 0.025 alpha threshold with a\np-value of 0.0320. The firm highlighted management's acknowledgment of\n\"unusual placebo performance, particularly among Latin America and Asia/Middle\nEast regions\" and referenced historic Phase 3 placebo responses ranging from\nnegative 9 meters to positive 11 meters, far below what PROSERA's placebo arm\nproduced.\n\nExecution Concerns on Wall Street\n\nOppenheimer's March 5, 2026 report was more pointed. The firm characterized\nthe Latin American data irregularity as \"a trial execution issue, not a drug\neffect issue,\" noting that key opinion leaders believed the anomaly pointed to\n\"human measurement error during 6MWD lap counting.\" This framing raised\nserious questions about clinical site monitoring and oversight, issues the\nlawsuit contends management knew or recklessly disregarded throughout the\nClass Period.\n\nWhy Analyst Shifts Matter for Investors\n* Wedbush cut its price target by 83%, from $6 to $1, and downgraded to\nNeutral\n* Oppenheimer reduced its target by 75%, from $12 to $3\n* Both firms identified the Latin American placebo response as the central\nproblem\n* Oppenheimer attributed the failure to trial execution rather than drug\nefficacy\n* Analyst models had been built on management's public assurances about\npatient selection quality\n* The severity of the downgrades reflects how far analyst expectations\ndiverged from the actual outcome\nThe lawsuit asserts that these analysts, like all public investors, were\nrelying on statements that omitted material information about the risk profile\nof Latin American enrollment sites.\n\n\"When analyst expectations are built on incomplete or misleading company\ndisclosures, the resulting corrections can cause significant investor harm.\nThe magnitude of these downgrades reflects the gap between what was\ncommunicated and what was known internally.\" -- Joseph E. Levi, Esq.\n\nJoin the GOSS recovery action\n(https://www.globenewswire.com/Tracker?data=0yYinrkuBwEvC96fjTjEM0MD-K2h226DDxwoRk6u90OENmKGtAknIIWrS-FOGPkceXwxSkgyLQ9dU9IF0j6k4mxmJBZ1ujfJyLOlUbNpEY0zzE9h5KJI7RJLAwtTwSOzW-jEZUIVvsIudMplCElgOAGraVXoPXA1q3YcdAMCcF7anch-roEEXgaRTvChb0sX)\nor call (212) 363-7500.\n\nABOUT LEVI & KORSINSKY, LLP -- Over the past 20 years, Levi & Korsinsky has\nsecured hundreds of millions of dollars for aggrieved shareholders. The firm\nhas extensive expertise in complex securities litigation and a team of over 70\nemployees. For seven consecutive years, Levi & Korsinsky has ranked in ISS\nSecurities Class Action Services' Top 50 Report. The last day to move for lead\nplaintiff is June 1, 2026.\n\nFrequently Asked Questions About the GOSS Lawsuit\n\nQ: How much did GOSS stock drop? A: Shares fell approximately 80%, a decline\nof $1.71 per share, after the Company disclosed that the Phase 3 PROSERA study\nfailed to meet the primary endpoint on February 23, 2026. Investors who\npurchased shares during the class period at artificially inflated prices may\nbe entitled to compensation.\n\nQ: What specific misstatements does the GOSS lawsuit allege? A: The complaint\nalleges Gossamer Bio made materially false or misleading statements regarding\nthe Phase 3 PROSERA trial design, patient selection quality, and trial\nexecution, while concealing that enrollment characteristics at Latin American\nsites created a high risk of an outsized placebo response. When the true state\nwas revealed, the stock price declined sharply.\n\nQ: What do GOSS investors need to do right now? A: Gather brokerage records\nincluding purchase dates, share quantities, and prices paid. Contact Levi &\nKorsinsky for a free, no-obligation evaluation at jlevi@levikorsinsky.com or\n(212) 363-7500. No immediate action is required to remain eligible as a class\nmember.\n\nQ: What if I already sold my GOSS shares -- can I still recover losses? A:\nYes. Eligibility is based on when you purchased, not whether you still hold\nthem. Investors who bought during the class period and sold at a loss may\nstill participate.\n\nQ: What does it cost me to participate? A: Nothing. Securities class actions\nare handled on a pure contingency basis. No upfront fees, no retainer, no\nout-of-pocket costs.\n\nQ: What if I missed the lead plaintiff deadline? A: The deadline applies only\nto investors seeking lead plaintiff appointment. Class members who miss it can\nstill participate in any settlement or recovery.\n\nCONTACT:\nLevi & Korsinsky, LLP\nJoseph E. Levi, Esq.\nEd Korsinsky, Esq.\n33 Whitehall Street, 27th Floor\nNew York, NY 10004\njlevi@levikorsinsky.com\nTel: (212) 363-7500\nFax: (212) 363-7171\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/d91bd4e6-7d18-43f7-a479-4f992242a82a)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-05-11T20:00:00.597712161Z","server_sent_at_ms":1778529600597},"received_at":"2026-05-11T20:00:00.806Z","source_url":null},"analysis":{"id":"22381","press_release_id":"30218","analysis_json":{"redFlags":[],"eventType":"legal_litigation","narrative":"Levi & Korsinsky, LLP issued a shareholder solicitation notice for Gossamer Bio, Inc. (NASDAQ: GOSS) after the company's stock fell 80% following the failure of its Phase 3 PROSERA study.\n\nThe lawsuit alleges that Gossamer Bio made materially false or misleading statements regarding the trial design, patient selection quality, and trial execution, particularly concerning the enrollment characteristics at Latin American sites.\n\nAnalyst firms Wedbush and Oppenheimer significantly downgraded their price targets and ratings, reflecting the severe loss of confidence in the company's management and clinical trial execution.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Plaintiff-firm solicitation -- suppress."},"keyFigures":{"eps":0,"epsBeat":0,"revenue":0,"guidance":"","revenueYoy":0,"dealValueUsd":0,"offeringPrice":0,"sharesOffered":0,"customDimensions":null},"quotedText":"When analyst expectations are built on incomplete or misleading company disclosures, the resulting corrections can cause significant investor harm. The magnitude of these downgrades reflects the gap between what was communicated and what was known internally.","namedEntities":{"people":[{"name":"Joseph E. Levi, Esq.","role":"attorney"},{"name":"Ed Korsinsky, Esq.","role":"attorney"}],"products":["seralutinib"],"companies":[{"name":"Gossamer Bio, Inc.","ticker":"GOSS"},{"name":"Levi & Korsinsky, LLP","relationship":"plaintiff law firm"},{"name":"Wedbush","relationship":"analyst firm"},{"name":"Oppenheimer","relationship":"analyst firm"}],"dollarAmounts":[{"amount":"$1.71","context":"per-share stock drop on February 23, 2026"}]},"materialImpact":{"score":1,"reasoning":"Plaintiff law-firm shareholder solicitation issued by Levi & Korsinsky. No new disclosure from the issuer; no certified class, no settlement. Boilerplate lead-plaintiff-deadline reminder."},"tickerRelevance":{"others":[],"primary":"GOSS"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Levi & Korsinsky, LLP issued a shareholder solicitation notice for Gossamer Bio, Inc. (NASDAQ: GOSS) after the company's stock fell 80% following the failure of its Phase 3 PROSERA study.\n\nThe lawsuit alleges that Gossamer Bio made materially false or misleading statements regarding the trial design, patient selection quality, and trial execution, particularly concerning the enrollment characteristics at Latin American sites.\n\nAnalyst firms Wedbush and Oppenheimer significantly downgraded their price targets and ratings, reflecting the severe loss of confidence in the company's management and clinical trial execution.","key_figures":{"eps":0,"epsBeat":0,"revenue":0,"guidance":"","revenueYoy":0,"dealValueUsd":0,"offeringPrice":0,"sharesOffered":0,"customDimensions":null},"named_entities":{"people":[{"name":"Joseph E. Levi, Esq.","role":"attorney"},{"name":"Ed Korsinsky, Esq.","role":"attorney"}],"products":["seralutinib"],"companies":[{"name":"Gossamer Bio, Inc.","ticker":"GOSS"},{"name":"Levi & Korsinsky, LLP","relationship":"plaintiff law firm"},{"name":"Wedbush","relationship":"analyst firm"},{"name":"Oppenheimer","relationship":"analyst firm"}],"dollarAmounts":[{"amount":"$1.71","context":"per-share stock drop on February 23, 2026"}]},"model_name":"Qwen/Qwen2.5-72B-Instruct-AWQ","prompt_hash":"sha256:a76fb3b19e8e8b7b","schema_hash":"sha256:8658c370b800cf3d","created_at":"2026-05-11T20:11:37.289Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"law-firm-solicitation","issuerAuthored":false}},"durationMs":138302,"modelName":"george-droid-qwen-72b"}}